Effectiveness of Trans-Arterial Chemo Embolization for Hepatocellular Carcinoma on Follow-Up CT Triphasic Liver
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- self admisistered questioner
研究概览
简要总结
"HCC is a major challenge due to greater recurrence rates and variable treatment responses. TACE is widely used, but its success relies on accurate follow-up imaging. CT Triphasic Liver Imaging plays a vital role in assessing treatment response, guiding clinical decisions, and improving patient outcomes. The purpose of this study is to investigate the relationship between response of treatment, gender, age, and the cause of HCC. The purpose of the study is to evaluate how well TACE (trans-arterial chemoembolization) works for patients with HCC.
详细描述
This will be a retrospective observational study aimed at evaluating the effectiveness of Trans-Arterial Chemo-Embolization in the management of Hepatocellular Carcinoma (HCC) using follow-up CT Triphasic Liver imaging. Patient records and imaging data from past cases will be reviewed to assess post- treatment tumor response and progression.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Both Male and Female.
- •Patients diagnosed with HCC who underwent TACE.
- •Patients with no portal vein tumor thrombus (PVTT) or no extra Extrahepatic Metastases at the time of initial TACE treatment.
- •Patients who underwent TACE within last your years from the study start date.
排除标准
- •Patients with incomplete or missing medical records and imaging studies.
- •Patients with a history of severe comorbidities that might interfere with treatment response evaluation
- •Patients who were contraindicated for CT scans at the time of follow-up.
- •Patients that are contradicted with CT scan.
- •Patient who underwent TACE more than four years before the study period.
结局指标
主要结局
self admisistered questioner
时间窗: 12 Months
self-administered questionnaire for the evaluation of HCCT, having a score range from 0 to 50. The more the score shows that issues worsen.
次要结局
未报告次要终点
研究者
Muhammad Naveed Babur
Principal Investigator
Superior University